Cargando…
Reimbursement for bone loss prevention is different between women with breast cancer and men with prostate cancer: time for a revision
The hormone dependent breast and prostate cancers have in general a very good survival, due to the anti-hormonal treatment. A disadvantage of this treatment is the increased risk of osteoporosis and fractures. It is surprisingly to note that denosumab has the same impact on fracture reduction incide...
Autor principal: | Tjalma, W.A.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Universa Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788334/ https://www.ncbi.nlm.nih.gov/pubmed/26977268 |
Ejemplares similares
-
HPV negative cervical cancers and primary HPV screening
por: Tjalma, WAA
Publicado: (2018) -
HPV vaccination coverage in the federal state of Belgium according to regions and their impact
por: Tjalma, WAA, et al.
Publicado: (2018) -
Is anti-hormonal treatment in DCIS of the breast a need?
por: Tjalma, WAA
Publicado: (2016) -
Cancer Treatment–Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer
por: Taxel, Pamela, et al.
Publicado: (2018) -
The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA
por: Baum, Charles, et al.
Publicado: (2015)